Australia markets open in 37 minutes

Heron Therapeutics, Inc. (HRTX)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
1.4400-0.0100 (-0.69%)
At close: 04:00PM EST
1.4800 +0.04 (+2.78%)
After hours: 04:43PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 217.61M
Enterprise value 320.19M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.54
Price/book (mrq)12.60
Enterprise value/revenue 2.61
Enterprise value/EBITDA -2.61

Trading information

Stock price history

Beta (5Y monthly) 1.51
52-week change 3-42.91%
S&P500 52-week change 316.10%
52-week high 33.4100
52-week low 30.5000
50-day moving average 30.9008
200-day moving average 31.5230

Share statistics

Avg vol (3-month) 32.95M
Avg vol (10-day) 33.26M
Shares outstanding 5150.07M
Implied shares outstanding 6155.25M
Float 8113.86M
% held by insiders 10.78%
% held by institutions 192.05%
Shares short (14 Nov 2023) 417.59M
Short ratio (14 Nov 2023) 45.85
Short % of float (14 Nov 2023) 413.50%
Short % of shares outstanding (14 Nov 2023) 411.72%
Shares short (prior month 12 Oct 2023) 419.36M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:20
Last split date 312 Jan 2014

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2022
Most-recent quarter (mrq)29 Sept 2023


Profit margin -97.45%
Operating margin (ttm)-66.26%

Management effectiveness

Return on assets (ttm)-24.51%
Return on equity (ttm)N/A

Income statement

Revenue (ttm)122.84M
Revenue per share (ttm)0.94
Quarterly revenue growth (yoy)18.40%
Gross profit (ttm)-50.51M
EBITDA -95.28M
Net income avi to common (ttm)-119.7M
Diluted EPS (ttm)-0.8800
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)77.41M
Total cash per share (mrq)0.52
Total debt (mrq)180M
Total debt/equity (mrq)N/A
Current ratio (mrq)2.43
Book value per share (mrq)-0.20

Cash flow statement

Operating cash flow (ttm)-98.78M
Levered free cash flow (ttm)-51.44M